Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Intestinal calcium transporter (TRPV6, PMCA1b, calbindin) and intestinal phosphate transporter (SLC34A2, NaPi-IIb)
- Molecular classification
- Transporter, Ion channel (TRPV6), ATPase (PMCA1b), Calcium-binding protein (calbindin), Sodium-phosphate cotransporter (SLC34A2)
01
Overview
Intestinal calcium and phosphate transporters are a group of membrane proteins and channels expressed by enterocytes responsible for the absorption of dietary calcium and phosphate across the intestinal epithelium. The main transporters for calcium include TRPV6 (an apical calcium channel), calbindin (an intracellular calcium-binding protein), and PMCA1b (a basolateral calcium ATPase). For phosphate, the principal transporter is the sodium-dependent phosphate transporter NaPi-IIb (SLC34A2). These systems are tightly regulated by hormones such as calcitriol (active vitamin D), parathyroid hormone, and fibroblast growth factor 23 to maintain systemic calcium and phosphate homeostasis critical for bone health and metabolic function. Disruption of transporter function leads to significant mineral balance disorders and is of therapeutic interest in metabolic bone and renal diseases.
- Other names
- Calcium channel, epithelial (TRPV6)Plasma membrane calcium ATPase 1b (PMCA1b)Calbindin-D9k (calcium-binding protein)Sodium-dependent phosphate transporter (NaPi-IIb, SLC34A2)Sodium-phosphate cotransporter familyIntestinal phosphate transporter
02
Mechanism of action
Stimulating or inhibiting transporter expression via hormone modulation (e.g., upregulation by calcitriol) Altering paracellular permeability via tight junction proteins under hormonal control
03
Biological functions
Intestinal absorption of calciumIntestinal absorption of phosphateSystemic mineral homeostasisBone mineralization
04
Disease associations
OsteoporosisRicketsHypophosphatemiaChronic kidney diseaseCalcium and phosphate metabolic disorders
05
Safety considerations
Dysregulation can result in hypercalcemia, hypocalcemia, hyperphosphatemia, or hypophosphatemiaAbnormal transporter function may contribute to kidney stones, bone demineralization, or vascular calcification
06
Interacting drugs
None directly approved targeting these specific intestinal transporters, but vitamin D analogs (like calcitriol) regulate their expression and activity
07
Biomarkers
Serum calcium (for calcium absorption function)Serum phosphate (for phosphate absorption function)Urinary calcium and phosphateExpression levels of TRPV6, calbindin, SLC34A2 (experimental)
Beyond the preview
Go deeper on Intestinal calcium transporter (TRPV6, PMCA1b, calbindin) and intestinal phosphate transporter (SLC34A2, NaPi-IIb).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Intestinal calcium transporter (TRPV6, PMCA1b, calbindin) and intestinal phosphate transporter (SLC34A2, NaPi-IIb).